Clinical Trial Applications - Approved: Filter, Search, and view applications


Clear
Extended search...

Page 39 of 58, showing 10 Applications out of 576 total, starting on record 381, ending on 390

# Protocol No Study Title Investigator(s) & Site(s) Date Approved

381.

ECCT/23/04/03   ACTIV-2d/A5407
    A Phase 3, multicenter, randomized, double-blind, 24-week study of the clinical and antiviral effect of S-217622 compared with placebo in non-hospitalized participants with COVID-19   
Principal Investigator(s)
1. Prof Abraham Mosigisi Siika
Site(s) in Kenya
1. MOI UNIVERSITY CLINICAL RESEARCH CENTRE (Uasin Gishu county)
2. Victoria Biomedical Research Institute, (Kisumu county)
3. Kenyatta National Hospital (Nairobi City county)
4. KEMRI CCR – BUTERE SITE (Kakamega county)
5. Kenya Medical Research Institute/Walter Reed Project (Kericho county)
6. KEMRI – AHERO Clinical Trials Units (Kisumu county)
 
14-06-2023 View

382.

ECCT/23/01/03   PRAISE
    An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (PRAISE)   
Principal Investigator(s)
1. Githanga Githanga Nyokabi
Site(s) in Kenya
1. Gertrude\'s Children Hospital (Nairobi City county)
2. Kondele Children\'s Hospital Center for Clinical Research (CCR), (Kisumu county)
3. KEMRI/CRDR Kemri Clinical Research Annex Siaya County Referral Hospital Grounds (Siaya county)
4. Kombewa CRC (Kisumu county)
 
19-06-2023 View

383.

ECCT/23/02/06   BOHEMIA Safety and Efficacy
    A Phase III cluster-randomized, open-label, clinical trial to study the safety and efficacy of ivermectin mass drug administration to reduce malaria transmission in Kwale, Kenya.         
Principal Investigator(s)
1. Marta Ferreira Maia
2. Joseph Mwangangi
Site(s) in Kenya
Kwale county, subcounties Lungalunga and Msambweni
 
25-06-2023 View

384.

ECCT/23/04/05   BiMVaC01
    A randomised, controlled clinical trial to assess and compare the immunogenicity, safety and reactogenicity of the bivalent Omicron BA.4/BA.5 adapted, and the original Wuhan-Hu-1-strain, BNT162b2 COVID-19 vaccine formulations in healthy unvaccinated East African adults.   
Principal Investigator(s)
1. NDUNGU FRANCIS
2. Said Jongo
Site(s) in Kenya
KEMRI-CGMRC Kilifi
 
06-07-2023 View

385.

ECCT/23/03/07   PLATINUM STUDY
    (PLATINUM): A multi-part, multi-center PLATform study to assess the efficacy, safety, tolerability and pharmacokinetics of anti-malarial agents administered as monotherapy and/or combination therapy IN patients with Uncomplicated Plasmodium falciparum Malaria   
Principal Investigator(s)
1. Godfrey (Site 5001) Allan Otieno
2. Bernhard Ragama Ogutu
3. John (Site 5002) Orimbo
Site(s) in Kenya
1. KEMRI Kondele Children Hospital (Kisumu county)
2. AHERO CLINICAL TRIALS UNIT (Kisumu county)
 
21-07-2023 View

386.

ECCT/23/02/03   INTREPiD
    Improving Neonatal Health Through Rapid Malaria Testing in Early Pregnancy with High-Sensitivity Diagnostics (INTREPiD).   
Principal Investigator(s)
1. Steve M Taylor
2. Jeremiah K Laktabai
Site(s) in Kenya
Bungoma County
 
23-07-2023 View

387.

ECCT/23/03/01   Micronutrient supplementation
    Optimizing nutrient supplementation among pregnant and reproductive age women in Kenya (Virutubisho)   
Principal Investigator(s)
1. DR. Martha Kaeni Mwangome
Site(s) in Kenya
KILIFI
 
24-07-2023 View

388.

ECCT/23/03/04   CONSTELLATION
    A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the effect of Bi-26 (strain of Bifidobacterium longum, B. infantis) supplementation versus placebo on weight gain in underweight infants   
Principal Investigator(s)
1. Dr Lucas Otieno Tina
Site(s) in Kenya
1. Victoria Biomedical Research Institute (Kisumu county)
 
31-07-2023 View

389.

ECCT/23/03/02   Sunrise-3
    A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients with COVID-19   
Principal Investigator(s)
1. Dr. Paul Yonga
2. Dr John Kinuthia
3. DR LUCAS OTIENO TINA
Site(s) in Kenya
1. Fountain Projects and Research Office, Clinical Research Centre (FOPRO-CRC) (Kisumu county)
2. KENYATTA NATIONAL HOSPITAL (Nairobi City county)
3. Victoria Biomedical Research Institute (VIBRI) (Kisumu county)
 
09-08-2023 View

390.

ECCT/23/03/05   SKY-06
    A PHASE II/III, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF TIRAGOLUMAB IN COMBINATION WITH ATEZOLIZUMAB PLUS   PEMETREXED AND CARBOPLATIN/CISPLATIN VERSUS PEMBROLIZUMAB PLUS PEMETREXED AND CARBOPLATIN/CISPLATIN IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER   
Principal Investigator(s)
1. Dr Primus Ochieng
Site(s) in Kenya
1. University of Nairobi -Institute of Tropical and Infectious Diseases (Nairobi City county)
2. International Cancer Institute (Uasin Gishu county)
 
11-08-2023 View